Anti-IL-6 chimeric monoclonal antibody
| Anti-IL-6 chimeric monoclonal antibody | |
|---|---|
| Term | Anti-IL-6 chimeric monoclonal antibody |
| Short definition | anti-IL-6 chimeric monoclonal antibody (AN-tee. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
anti-IL-6 chimeric monoclonal antibody - (pronounced) (AN-tee. . . ky-MEER-ik MAH-noh-KLOH-nul AN-tee-BAH-dee) drug used to treat a rare condition called multicentric Castleman disease in patients who are not infected with HIV or human herpesvirus 8. It is also being studied to treat some cancers and other conditions. The anti-IL-6 chimeric monoclonal antibody binds to a protein called interleukin-6 (IL-6), which is made by some white blood cells and other cells in the body. Anti-IL-6 chimeric monoclonal antibody may help reduce inflammation and stop the growth of cancerous or abnormal blood cells. It's a type of monoclonal antibody. Also referred to as cCLB8, CNTO 328, Siltuximab and Sylvant
External links
- Medical encyclopedia article on Anti-IL-6 chimeric monoclonal antibody
- Wikipedia's article - Anti-IL-6 chimeric monoclonal antibody
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski